Navigation Links
Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
Date:8/24/2009

muscle-invasive bladder cancer.

In September, 2007, the Company announced that an agreement had been reached with the FDA under the Special Protocol Assessment (SPA) procedure on the design of the trial, including its endpoints, data analysis and conduct. It provides assurance that, if the trial endpoints are met, they will serve as the basis for product approval under a Biologics Licensing Application (BLA). An SPA gives a clear pathway to registration of Urocidin when the trial endpoints are achieved. This indication for MCC received Fast Track designation by the FDA last year.

About Bladder Cancer

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70 percent of bladder cancer patients have the non-muscle-invasive form of bladder cancer at diagnosis and, on appropriate regulatory approvals, might be eligible for multiple treatments with Urocidin.

Non-muscle-invasive bladder cancer is a form of bladder cancer localized in the surface layers of the bladder that has not yet spread into the deeper muscle layer. This form of bladder cancer is treated predominantly by urologists using surgical resection and intravesical infusion therapy. Urocidin is an intravesical infusion therapy, administered via trans-urethral catheter into the bladder.

About Urocidin(TM)

Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. Urocidin is formulated for the treatment of bladder cancer, where it is administered by trans-urethral catheter directly into the bladder, coming into con
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bioniche Repays Revolving Credit Facility
2. Bioniche Provides a Corporate Update
3. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
4. Bioniche Represented at House of Commons Sub-Committee on Food Safety
5. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
6. Bioniche Reports Fiscal 2009 Third Quarter
7. Bioniche Provides a Corporate Update
8. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
9. Bioniche Revolving Credit Facility Maturity Date Amended
10. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
11. Bioniche Warrants Expiration Date to be Extended
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... State University biochemists have discovered a family of proteins ... aureus , a pathogenic bacterium that can cause more ... Geisbrecht, professor of biochemistry and molecular biophysics, and Kasra ... , which is the cause of increasing common staph ... Proceedings of the National Academy of Sciences , or ...
(Date:9/2/2014)... have made it clear that a mother,s eating habits ... a profound impact on her offspring and their propensity ... now, the mechanisms behind this phenomenon were unclear. According ... of The FASEB Journal F , scientists ... a mother,s diet and an offspring,s risk of future ...
(Date:9/2/2014)... Many people believe that marijuana is not addictive, but ... people are able to obtain and consume cannabis legally ... are less likely to perceive it as addictive or ... General Hospital,s Center for Addiction Medicine, said in a ... use can have significant consequences, and we know that ...
(Date:9/2/2014)... Malvern, PA (PRWEB) September 02, 2014 ... healthcare communications and education, is proud to announce the ... and clinical resource center designed for healthcare professionals who ... website offers practitioners comprehensive access to:, , ... , Dedicated topic centers for diabetes, oncology, ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Healthcare professionals ... and most complete oncology guidelines available at the point ... and the National Comprehensive Cancer Network® ... other evidence and guidelines in the content available from ... , NCCN, a not-for-profit alliance of 25 of the ...
Breaking Medicine News(10 mins):Health News:Biochemists find new treatment options for staph infections, inflammatory diseases 2Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:'Pot Addiction' May Be Real, Study Suggests 2Health News:HMP Communications Holdings, LLC, Acquires Nutrition411.com 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4
... growth of cancer cells in lab study , THURSDAY, Nov. ... form of leukemia holds promise as a possible treatment for ... (Sprycel) is used to treat chronic myeloid leukemia. Researchers at ... drug limited the growth and invasive powers of ovarian cancer ...
... ... and his company, Nationwide Relocation Services, are enormous supporters of breast cancer ... lethal disease are growing by number, as both men and women are ... its power to assist in costumers, moves when coping with such difficult ...
... ... PDF conversion product line. PDF2Office® for iWork a new product to convert PDF to ... ... Recosoft Corporation the developer of the PDF2Office® family of products, PDF2ID® tool for InDesign®, ...
... ... are under even more pressure to perform during the swine flu ... large and small over the coming months. While some large businesses ... for their employees, many medium and smaller businesses are not protected. ...
... FREEHOLD, N.J., Nov. 11 Speedus Corp. (Nasdaq: SPDE ... Graham was appointed to the Company,s Board of Directors. , ... which he founded in 1988, and has been a General ... Crosshill Debt II, L.P. since 2004. Prior to these roles ...
... Forward thinking Mayor A.C. Wharton, sees Benefit in New ... Memphis Mayor, A.C. Wharton stands up for the outstanding ... hosted by University of Tennessee Health & Science Center on ... Madison in Room 305. The National Bipolar Foundation has been ...
Cached Medicine News:Health News:Leukemia Drug May Help Some Ovarian Cancer Patients 2Health News:Nationwide Relocation Services Support Breast Cancer Awareness 2Health News:Nationwide Relocation Services Support Breast Cancer Awareness 3Health News:PDF2Office for iWork -- New Utility to Convert PDF Files Directly to Native Keynote & Pages '08/'09 Formats Ships 2Health News:PDF2Office for iWork -- New Utility to Convert PDF Files Directly to Native Keynote & Pages '08/'09 Formats Ships 3Health News:How to Survive Recession and Swine Flu Outbreak in Your Employees 2Health News:Speedus Corp. Names Stephen X. Graham to Board of Directors 2Health News:Memphis Mayor Endorses National Bipolar Foundation 2
(Date:9/2/2014)... , Spanien, September 2, 2014 ... Das auf dem ESC-Kongress 2014 präsentierte ... Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten Patienten ... Die Daten der ... Patienten, einer innovativen und unabhängigen Forschungsinitiative ...
(Date:9/2/2014)... September 2, 2014 , ... 2014 provide insight into treatment and outcomes of ... practice --   Data from nearly ... in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent ... strategies for atrial fibrillation (AF) patients remain sub-optimal ...
(Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, the ... its investment in development and manufacturing capabilities with the ... Karl Mueller , Particle Sciences, Associate Director Clinical Production, ... adding clean room square footage, equipment and staff across ... The company now has over 6000ft 2 of ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
... , ... The Gamida Cell-Teva Joint Venture,(JV) announced today that the ... registration, Phase,III clinical trial of StemEx (called ExCell) and has recommended ... data analysis is,anticipated to take place during Q2 2010. StemEx is ...
... , Feb. 9 CareFusion Corp. (NYSE: ... from continuing operations for the three and six months ended ... during our second quarter and performed ahead of our expectations," said ... spending made modest improvements during the quarter and we continued to ...
Cached Medicine Technology:Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 2Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 3CareFusion Reports Second Quarter Results 2CareFusion Reports Second Quarter Results 3CareFusion Reports Second Quarter Results 4CareFusion Reports Second Quarter Results 5CareFusion Reports Second Quarter Results 6CareFusion Reports Second Quarter Results 7CareFusion Reports Second Quarter Results 8CareFusion Reports Second Quarter Results 9CareFusion Reports Second Quarter Results 10CareFusion Reports Second Quarter Results 11CareFusion Reports Second Quarter Results 12CareFusion Reports Second Quarter Results 13CareFusion Reports Second Quarter Results 14CareFusion Reports Second Quarter Results 15CareFusion Reports Second Quarter Results 16CareFusion Reports Second Quarter Results 17CareFusion Reports Second Quarter Results 18
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... perfecting mini-invasive endoscopic methods for ensuring extremely ... considerable social impact. The use of these ... and represents a valid backup in cutting ... family of Nd:YAG lasers is growing, developing ...
... hair removal for all skin ... Used for leg and facial ... Offers a large spot sizes ... fast treatment. An optional ...
Medicine Products: